Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC
R. Katie Kelley, MD, discusses updated safety data on tremelimumab plus durvalumab for patients with advanced hepatocellular carcinoma.
EP: 1.Overview of Hepatocellular Carcinoma (HCC)
EP: 2.Diagnosing Patients With Hepatocellular Carcinoma
EP: 3.Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC
EP: 4.Treatment Approaches for Patients With Early-Stage HCC
EP: 5.The Role of Adjuvant Therapy in Patients With Early-Stage HCC
EP: 6.Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial
EP: 7.Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study
EP: 8.Optimal Sequencing in Patients With Advanced HCC
EP: 9.Safety Profiles of Available Therapies in Advanced HCC
EP: 10.The Future of HCC Treatment
EP: 11.First-Line Systemic Treatment Options for Patients With Advanced HCC
EP: 12.Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study
Now Viewing
EP: 13.Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC
EP: 14.The CELESTIAL Study: Cabozantinib Monotherapy in Advanced HCC Treatment
EP: 15.Safety and Efficacy Data From the Retrospective Analysis of the CELESTIAL Study in Advanced HCC
EP: 16.Future of Advanced HCC Treatment
Related Videos
Related Content
